Close

Prof John Kelly

Professor of Molecular Biology

London School of Hygiene & Tropical Medicine
Keppel street
London
WC1E 7HT
United Kingdom

Tel.
+44 207 927 2330
Research area: The molecular biology of parasitic protozoa

My lab focuses on four main areas:

Development of new genetic tools for functional studies on Trypanosoma cruzi
Mechanisms of drug action and resistance in Chagas disease
Anti-trypanosome drug development
Understanding Chagas disease pathogenesis

Funding: Medical Research Council, Drugs for Neglected Diseases initiative (DNDi), GSK, Novartis

Affiliations

Department of Infection Biology
Faculty of Infectious and Tropical Diseases

Centres

Malaria Centre
Antimicrobial Resistance Centre

Teaching

I teach on modules offered by LSHTM as part of their taught course MSc portfolio. These lectures cover molecular parasitology and drug development. I also deliver lectures on trypanosome biology at the University of Cambridge. Currently, I supervise 3 PhD students.

Research

The parasitic protozoa Trypanosoma cruzi and Trypanosoma brucei are responsible for two major tropical infections, Chagas disease and African trypanosomiasis, respectively. These diseases represent a major public health problem in regions of the world least able to deal with the associated economic burden. Advances by ourselves and others have led to the development of a wide range of genetic tools that can be used to address fundamental biological questions associated with these important pathogens. In addition, the output of the trypanosomatid genome projects, together with major advances in imaging technology is providing a research framework where rapid progress can be expected. We are exploiting these new approaches and opportunities to gain greater understanding of the mechanisms of drug action and resistance, and disease pathogenesis. In collaboration with biologists, biochemists and medicinal chemists, we are contributing to the Chagas disease drug discovery pipeline, as well as providing the community with new functional genomic tools. These multidisciplinary approaches, which bring together of both academic and industrial partners, is now widely seen as the way ahead to provide better treatment for these previously ‘Neglected Diseases’.
Research Area
Genomics
Immunopathology
Biochemistry
Cell biology
Molecular biology
Parasitology
Pathology
Drug discovery and development
Drug resistance
Parasites
Trypanosomes
Research methodology
Protozoa
Disease and Health Conditions
Chagas disease
African trypanosomiasis
Leishmaniasis
Country
Argentina
Brazil
Colombia
Mexico
United States of America
Region
Latin America & Caribbean (all income levels)
Sub-Saharan Africa (developing only)

Selected Publications

Synthesis and Anti-Chagas Activity Profile of a Redox-Active Lead 3-Benzylmenadione Revealed by High-Content Imaging
Trometer, N; Pecourneau, J; Feng, L; Navarro-Huerta, JA; Lazarin-Bidóia, D; De Oliveira Silva Lautenschlager, S; Maes, L; FORTES FRANCISCO, A; KELLY, JM; Meunier, B; Cal, M; Mäser, P; Kaiser, M; Davioud-Charvet, E;
2024
ACS Infectious Diseases
A panel of phenotypically and genotypically diverse bioluminescent:fluorescent<i>Trypanosoma cruzi</i>strains as a resource for Chagas disease research
Olmo, F; Jayawardhana, S; Khan, AA; Langston, HC; FRANCISCO, AF; Atherton, RL; Ward, AI; Taylor, MC; KELLY, JM; Lewis, MD;
2024
Cold Spring Harbor Laboratory
02082023 Comparison of the efficacy of DNDI0003974228 and benznidazole in combination with posaconazole against chronic T. cruzi infection using in vivo bioluminescence imaging
Fortes Francisco, A; KELLY, J;
2024
Comparison of the efficacy of DNDI0003974228 and benznidazole in combination with posaconazole against chronic T. cruzi infection using in vivo bioluminescence imaging
26062023 Comparison of the efficacy of DNDI0003578526, DNDI0003975824, DNDI0003974228 and benznidazole in combination with posaconazole against chronic T. cruzi infection using in vivo bioluminescence imaging
Fortes Francisco, A; KELLY, J;
2023
Comparison of the efficacy of DNDI0003578526, DNDI0003975824, DNDI0003974228 and benznidazole in combination with posaconazole against chronic T. cruzi infection using in vivo bioluminescence imaging
Short-course combination treatment for experimental chronic Chagas disease.
González, S; WALL, RJ; Thomas, J; Braillard, S; Brunori, G; Camino Díaz, I; Cantizani, J; Carvalho, S; Castañeda Casado, P; Chatelain, E; Cotillo, I; Fiandor, JM; FRANCISCO, AF; Grimsditch, D; Keenan, M; KELLY, JM; Kessler, A; Luise, C; Lyon, JJ; MacLean, L; Marco, M; Martin, JJ; Martinez Martinez, MS; Paterson, C; Read, KD; ... De Rycker, M.
2023
Science translational medicine
24112023 Comparison of the efficacy of HT 759 against acute T. cruzi infection using in vivo bioluminescence imaging
Fortes Francisco, A; KELLY, J;
2023
Comparison of the efficacy of HT 759 against acute T. cruzi infection using in vivo bioluminescence imaging
Optimisation-based modelling for explainable lead discovery in malaria.
Li, Y; Cardoso-Silva, J; KELLY, JM; DELVES, MJ; FURNHAM, N; Papageorgiou, LG; Tsoka, S;
2023
Artificial intelligence in medicine
Cardiac Abnormalities in a Predictive Mouse Model of Chagas Disease.
FRANCISCO, AF; Sousa, GR; Vaughan, M; Langston, H; KHAN, A; Jayawardhana, S; TAYLOR, MC; Lewis, MD; KELLY, JM;
2023
Pathogens
Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice.
Jayawardhana, S; Ward, AI; FRANCISCO, AF; Lewis, MD; TAYLOR, MC; KELLY, JM; Olmo, F;
2023
PLoS Pathogens
Dynamics of Trypanosoma cruzi infection in hamsters and novel association with progressive motor dysfunction
Langston, H; FORTES FRANCISCO, A; Doidge, C; ROBERTS, CH; Khan, AA; Jayawardhana, S; TAYLOR, MC; KELLY, JM; Lewis, MD;
2023
PLoS Neglected Tropical Diseases
See more information